Monte Rosa Therapeutics, Inc. beat EPS estimates 0% of the time across 3 reported quarters (0 beats, 3 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.25 | $-0.43 | -72.0% | Miss |
| Q12026 FY2026 | $-0.28 | $-0.45 | -60.7% | Miss |
| Q42025 FY2025 | $-0.47 | $-0.55 | -17.0% | Miss |
Back to GLUE overview · GLUE holders · GLUE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.